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Myeloid differentiation primary 
response gene (MyD) 88 signalling 
is not essential for intestinal fibrosis 
development
C. Lutz1, B. Weder1, A. Hünerwadel1, S. Fagagnini1, B. Lang2,3, N. Beerenwinkel  2,3,  
J. B. Rossel4, G. Rogler1, B. Misselwitz1 & M. Hausmann1
Dysregulation of the immune response to microbiota is associated with inflammatory bowel disease 
(IBD), which can trigger intestinal fibrosis. MyD88 is a key component of microbiota signalling but its 
influence on intestinal fibrosis has not been clarified. Small bowel resections from donor-mice were 
transplanted subcutaneously into the neck of recipients C57BL/6 B6-MyD88tm1 Aki (MyD88−/−) 
and C57BL/6-Tg(UBC-green fluorescence protein (GFP))30Scha/J (GFP-Tg). Grafts were explanted up 
to 21 days after transplantation. Collagen layer thickness was determined using Sirius Red stained 
slides. In the mouse model of fibrosis collagen deposition and transforming growth factor-beta 1 
(TGF-β1) expression was equal in MyD88+/+ and MyD88−/−, indicating that MyD88 was not essential 
for fibrogenesis. Matrix metalloproteinase (Mmp)9 expression was significantly decreased in grafts 
transplanted into MyD88−/− recipients compared to MyD88+/+ recipients (0.2 ± 0.1 vs. 153.0 ± 23.1, 
respectively, p < 0.05), similarly recruitment of neutrophils was significantly reduced (16.3 ± 4.5 vs. 
25.4 ± 3.1, respectively, p < 0.05). Development of intestinal fibrosis appears to be independent of 
MyD88 signalling indicating a minor role of bacterial wall compounds in the process which is in contrast 
to published concepts and theories. Development of fibrosis appears to be uncoupled from acute 
inflammation.
Innate immunity plays a pivotal role in IBD, with its two entities Crohn’s disease (CD) and ulcerative colitis 
(UC)1. In IBD, the intestinal microbiota leads to a response by the innate immune system causing inflammation. 
Dedicated extracellular and intracellular pattern recognition receptors, such as ten different Toll-like receptors 
(TLRs) and NOD-like receptors with at least 23 variants in the human genome, are responsible for sensing local 
microbiota2. TLR stimulation triggers an intracellular cascade via the cytoplasmic Toll/interleukin-1 (IL-1) recep-
tor (TIR) signalling domain. TLR signalling depends critically on a total of four adaptor proteins — MyD88, TIR 
adaptor protein (TIRAP, also called MAL), (TIR)-containing adapter molecule 1 (TICAM1, also called TRIF), 
and TICAM2 (also called TRAM) — that directly bind to activated TLRs and recruit downstream signalling 
components3. MyD88 is a TIR domain-containing adaptor protein for the induction of inflammatory cytokines 
triggered by all TLRs with the exception of TLR33 and is expressed in a variety of cells4–6. Signalling via MyD88 
leads to the activation of downstream nuclear transcription factors such as nuclear factor-kB (NF-kB), cyclic 
AMP response element-binding protein and AP-1 ensuring the production of pro-inflammatory cytokines such 
as tumor necrosis factor (TNF) and IL-1, chemokines and other soluble mediators with subsequent inflammation 
and leukocyte accumulation2.
Dysregulated microbiota signalling is associated with IBD pathophysiology. Epidemiological studies of the 
pattern recognition receptors upstream of MyD88 clearly show an association between TLR47, TLR58 and TLR99 
polymorphisms and susceptibility to IBD. TLR1, TLR2 and TLR6 variants were found to be associated with dis-
ease phenotypes10. A genetic variant in the gene encoding TIRAP, necessary to recruit MyD88 to TLR2 and TLR4 
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has an effect on the risk of IBD11. Equally, for components downstream of MyD88 studies show an association 
between signalling dysfunction and IBD12,13. MyD88 can be viewed as a focal point for microbiota signalling 
involved in the signal transduction of almost all TLRs and causing inflammation. Studies have identified patients 
with mutations in MYD88 that abolish protein production and result in a primary immunodeficiency syndrome 
characterized by greater susceptibility to pyogenic bacteria14–16. Three different autosomal recessive mutations 
have been described in MYD88-deficient patients suffering from recurrent infections with pyogenic bacteria. 
Life-threatening infections in subjects with defective MyD88 first occur during early infancy14.
Thus, one would also expect an association between MyD88 polymorphisms or its dysregulated expression 
and a susceptibility to IBD. A total of 163 IBD loci that meet genome-wide significance thresholds were found 
by analysis of data from 15 genome-wide association studies of CD and UC combined with Immunochip valida-
tion17. However, disease-associated MyD88 polymorphisms were not described. Further studies showed that the 
MyD88 polymorphism rs7744 is closely associated with the development of UC and that this polymorphism may 
be linked with the response to UC therapeutic approaches18. The function of rs7744 has not been clearly identi-
fied, although minor allele variants is thought to lead to an overexpression of the MyD88 protein18, considering 
the increased mRNA and protein levels of MyD88 in UC patients19.
Fibrosis is increasingly being recognised as an important cause of morbidity and mortality in IBD. While the 
triggering of fibrosis seems to require inflammation as a prerequisite step, the mechanisms involved in the pro-
gression of fibrogenesis may be distinct. There is evidence that intestinal fibrogenesis after being initiated is - at 
least to some extent - a self-perpetuating process20. Administration of potent anti-inflammatory agents effectively 
treats inflammatory flares, but at present there is no specific treatment option for patients with recurrent intes-
tinal fibrosis21,22. Notable progress has been made in elucidating therapeutic targets to tackle the inflammatory 
component of IBD, but the incidence of strictures and of subsequent surgical interventions remains relatively 
unchanged23.
In this current study we describe the role of the MyD88-dependent innate immunity pathway in the fibro-
genic process. We applied the rapid and reliable heterotopic transplantation model of intestinal fibrosis24 to 
MyD88-deficient mice. Our data suggests that the development and progression of fibrosis in the intestine is 
not dependent on MyD88 signalling but alludes to the presence of alternative pathways which contribute to this 
process. This suggests that anti-inflammatory agents – although essential to treat inflammatory flares – are not a 
sufficient treatment option against IBD-associated fibrosis.
Materials and Methods
All experiments were performed in accordance with relevant guidelines and regulations.
Animals. C57BL/6 B6-MyD88tm1 Aki (MyD88−/−) and C57BL/6-Tg(UBC-green fluorescence protein 
(GFP))30Scha/J (GFP-Tg) mice weighing 20 g were obtained from Jackson Laboratories and bred locally. 
The animals received standard laboratory mouse food and water ad libitum. They were housed under specific 
pathogen-free conditions in individually ventilated cages. The experimental protocol was approved by the local 
Animal Care Committee of the University of Zurich (registration numbers 114/2011 and ZH183/2014).
Heterotopic intestinal transplant model. The heterotopic mouse intestinal transplant model is an adap-
tion of the transplantation model of intestinal fibrosis in rats. Both have been previously described in detail24,25. 
In short, donor small bowel was resected and transplanted subcutaneously into the neck of recipient animals. 
Intestinal grafts were explanted up to 21 days after transplantation. At explantation, each graft was divided into 
three equal segments. One segment was fixed in 4% formalin and prepared for histopathological assessment. The 
other segments were snap frozen in liquid nitrogen and stored at −80 °C until RNA extraction.
RNA isolation, cDNA synthesis and real-time PCR. For isolation of total RNA, lysis buffer from the 
RNeasy® kit (Qiagen, Hilden, Germany) was added to snap frozen resections. Samples were shredded in M tubes 
(# 130-093-236, Miltenyi Biotec) in a gentle MACSTM dissociator (Miltenyi Biotec). Total RNA was prepared 
according to the manufacturer’s protocol and stored at −80 °C. Quality of total RNA was controlled with the 
Agilent 2100 expert EukaryoteTotal RNA Nano Assay. Only RNA with a RNA integrity number > 6 was used for 
analysis. The isolated RNA was reverse-transcribed using a Reverse Transcription System (Applied Biosystems). 
Quantitative mRNA analysis by real-time PCR was performed using Taqman® gene Expression Assays for mouse 
collagen type I alpha 1 (Col1a1) Mm00801666_g1, TGF-β1 Mm01178820_m1, MMP-9 Mm00442991_m1, tissue 
inhibitor of matrix metalloproteinase 1 (TIMP-1) Mm00441818_m1, hypoxia inducible factor 1 alpha subunit 
(HIF-1α) Mm01283760_m1 and GAPDH # 4352339E TaqMan® Gene Expression Assays. The relative cDNA 
concentration for the gene of interest was calculated using the ddCt-method.
Immunohistochemistry (IHC). TGF-β1 was stained with a rabbit polyclonal antibody from Santa Cruz 
Biotechnology Inc. (#sc-146, dilution 1:200, immunstainer Leica Bond III Stainer, pretreatment: Bond Epitop 
Retrival Buffer 2 for 20 min., detections kit: Bond Polymer Refine Detections Kit, all reagents from Bond Leica). 
The sections were examined with the Imager Z2 microscope (Zeiss) and AxioVision software (Zeiss).
Sirius Red-stained slides were analyzed by bright-field microscopy with an additional polarizing filter. Under 
polarized light Sirius Red-stained collagen assumes a palette of colors ranging from green to red based on the 
fibrotic maturation process. Collagen layer thickness was determined by an investigator blinded to the experi-
ment. Thickness was measured in at least eight places in representative areas at 10-fold magnification. Similarly 
slides were stained with Elastica van Gieson and analyzed using transmission light microscopy. Collagen layer 
thickness was determined as previously described for Sirius Red staining.
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Statistical analysis. Statistical analysis for real time PCR and collagen layer thickness was performed using 
Kruskal-Wallis one way analysis of variance on ranks, all pairwise multiple comparison procedures, Dunn’s 
method. Comparison between genotypes was performed using the Mann-Whitney-Test for each time point. 
Differences were considered significant at a p-value of <0.05 (*) and highly significant at a p-value of < 0.01 (**) 
and p-value of < 0.001 (***).
Ethical considerations. The experimental protocol for animals was approved by the local Animal Care 
Committee of the University of Zurich (registration numbers 114/2011 and ZH183/2014).
Results
Development of intestinal fibrosis is not prevented in grafts extracted from GFP-Tg donor 
animals and transplanted into MyD88−/− recipients. To determine the relevance of MyD88 in the 
development of fibrosis, MyD88−/− and GFP-Tg mice were used as both donors and recipients for isogeneic 
transplantation in our heterotopic animal model of intestinal fibrosis. The presence of endogenous GFP in 
GFP-Tg donor or recipient mice allowed for a genotype-specific staining. Body weight remained unchanged 
in both MyD88−/− and GFP-Tg recipients (not shown). Grafts were explanted up to 21 days after transplanta-
tion as indicated. 26 isogeneic transplants (GFP-Tg into GFP-Tg mice), 58 isogeneic transplants (GFP-Tg into 
MyD88−/− mice) and 47 isogeneic transplants (MyD88−/− into GFP-Tg mice) were performed. Of 131 transplants 
histologically evaluable tissue was recovered from all but 7 grafts. To compare grafts with non-transplanted tissue 
28 small bowel resections were extracted from GFP-Tg mice and six small bowel resections were extracted from 
MyD88−/− mice.
Exaggerated collagen deposition is a histologic and molecular hallmark of human intestinal fibrosis, therefore 
Col1a1 mRNA expression was analyzed by real-time PCR (Fig. 1A). Col1a1 mRNA increased in a time-dependent 
manner. Col1a1 mRNA expression was significantly increased 5 days after transplantation in isogeneic trans-
plants of GFP-Tg into GFP-Tg mice, GFP-Tg into MyD88−/− mice and MyD88−/− into GFP-Tg mice com-
pared to freshly isolated small intestine (Figs. 1A, 177.3 ± 86.09 vs. 209.6 ± 73.62 vs. 1.00 ± 0.11, p < 0.01 (**) 
Figure 1. Development of intestinal fibrosis is not prevented in grafts extracted from GFP-Tg donor animals 
and transplanted into MyD88−/− recipients. (A) Col1a1 mRNA expression is significantly increased over 
time compared to freshly isolated intestine (p < 0.05 (*), p < 0.01(**), error bars = SEM, n = as indicated). 
(B) Sirius Red staining. Transmission light showed increased collagen layer thickness in grafts at day seven 
in comparison to freshly isolated intestine. Polarizing light microscopy confirmed increased collagen layer 
thickness at day seven. Representative figures from n = 3. (C) Thickness was calculated from at least eight 
places in representative areas at 10-fold magnification for each single graft. Collagen layer thickness increased 
significantly in grafts over time. Mean value and SEM is shown (p < 0.01 (**), n = 8 – 16 for each column).
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and 198.9 ± 52.6 vs. 0.86 ± 0.15, p < 0.05 (*) respectively, n = as indicated). The development of Col1a1 mRNA 
expression curves over time is similar in grafts of both genotypes.
The development of intestinal fibrosis after heterotopic transplantation was also observed in histological cross 
sections. Collagen production and deposition in the intestinal transplants was determined by Sirius red staining 
under transmission and polarizing light microscopy (Fig. 1B). In Sirius red-stained histological cross-sections 
freshly isolated small intestine was characterized by an open lumen and distinctive epithelial crypts (Fig. 1B). 
At day 7 after transplantation the lumen of intestinal grafts was obstructed by granulation tissue and fibrotic 
material. Freshly isolated small intestine was characterized by mostly long-chained collagen (red stain) adjacent 
to the submucosa. The presence of short-chained collagen (green and yellow stain) increased continuously in the 
submucosa and in the luminal occlusion after transplantation. Loss of epithelial structures and luminal occlusion 
was observed irrespective of the genotype of donor and recipient mice. Time dependent increase in collagen was 
also confirmed by Elastica van Gieson (EvG) staining (Supplementary Figure 1).
The collagen layer thickness in harvested grafts was significantly increased in comparison to the collagen 
layer thickness in freshly isolated small intestine (Fig. 1C, p < 0.01 (**), calculated from n = number of grafts as 
indicated). Collagen layer thickness is comparable between grafts in both MyD88−/− and GFP-Tg recipients over 
time.
Myd88 is not required for an increase in Hif1α expression after heterotopic small bowel trans-
plantation. MyD88 signaling regulates Hif-1α expression26. Therefore Hif1α mRNA expression was analyzed 
by real-time PCR to determine hypoxia-mediated signalling (Fig. 2). Surprisingly Hif1α mRNA was unchanged 
for at least 48 hours in grafts of both genotypes. This was followed by a significantly increased Hif1α mRNA 
expression after 4 days in isogeneic transplants of both GFP-Tg into MyD88−/− mice as well as MyD88−/− into 
GFP-Tg mice compared to freshly isolated small intestine (Fig. 2, 2.90 ± 0.89, vs. 1.00 ± 0.01 and 3.60 ± 0.52 vs. 
0.77 ± 0.23, respectively, *p < 0.05, n = 3 each column). The development of Hif1α mRNA expression over time 
is similar in grafts of both genotypes.
Previously, we could show that macroscopically visible blood vessels from the surrounding tissue extend 
towards the graft where they form a dense vascular network. In this study we determined the origin of the 
lumen-obstructing cells in isogeneic transplants (MyD88−/− into GFP-Tg mice). As expected, the freshly isolated 
intestinal resections from MyD88−/− mice are negative for GFP staining (Supplementary Figure 2A and B). An 
increase in infiltration of stained GFP cells ensued in a time-dependent manner. Initially, red-stained cells were 
visible exclusively in the submucosa and seemed to accumulate along the collagen layer. Subsequent time-points 
showed progressive infiltration along the crypts and into the lumen. As seen in GFP staining, the infiltrating cells 
frequently enter the graft not in a diffuse, but rather in a more localized fashion, with specific points of access 
forming along the graft wall (Supplementary Figure 2B). They then pour across the tissue and into the lumen 
contributing to the total occlusion of the graft. Seven days after transplantation GFP positive blood vessels appear 
within the GFP negative donor tissue (Supplementary Figure 2C). This result demonstrates an increased infiltra-
tion to the graft via blood vessels irrespective of MyD88-driven signalling.
Induction Tgfβ1 mRNA expression during fibrosis is independent from Myd88. To further 
substantiate that fibrosis evolves independently from MyD88 signalling, expression of Tgfβ1 was analyzed. 
Tgfβ1 mRNA expression was increased in a time-dependent manner (Fig. 3A). Tgfβ1 mRNA expression was 
significantly increased 5 days after transplantation in isogeneic transplants of both GFP-Tg into GFP-Tg mice, 
in isogeneic transplants of both GFP-Tg into MyD88−/− mice and MyD88−/− into GFP-Tg mice compared to 
freshly isolated small intestine (5.20 ± 2.1, vs. 1.00 ± 0.9, 3.61 ± 0.98, vs. 1.00 ± 0.9 and 4.00 ± 0.73 vs. 1.18 ± 0.21 
respectively, p < 0.05 (*), n = as indicated). Similar results were obtained 21 days after transplantation com-
pared to freshly isolated small intestine (GFP-Tg into GFP-Tg mice: 6.20 ± 1.3, vs. 1.00 ± 0.9, GFP-Tg into 
Figure 2. Myd88 is not required for an increase in Hif1α expression after heterotopic small bowel 
transplantation. Real time PCR confirmed significant increase of Hif1α expression over time (p < 0.05 (*), 
n = as indicated). Error bars = SEM.
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MyD88−/− mice: 5.17 ± 1.33, vs. 1.00 ± 0.9 and MyD88−/− into GFP-Tg mice: 4.99 ± 1.42 vs. 1.18 ± 0.21 respec-
tively, p < 0.05 (*), n = as indicated). Tgfβ1 mRNA expression was similar between grafts of both genotypes over 
time. TGF-β1 was also detected by IHC along the crypt villus axis in mouse intestinal epithelial cells in freshly 
isolated intestine (Fig. 3B). No TGF-β1 was detected in the lamina propria. Intense staining for TGF was found in 
the luminal occlusion from day 5 to day 21 in isografts of both MyD88−/− and GFP-Tg recipients.
MyD88 deficiency reduces intestinal inflammation but not the development of intestinal fibro-
sis. MyD88-signalling is an inducer of MMP-9 expression27,28. As MMPs are involved in mucosal fibrosis we 
determined the expression of tissue remodeling protease MMP-9 and the tissue inhibitor of metalloproteinases 
TIMP-1 in intestinal transplants by real-time PCR. Mmp9 mRNA expression was increased in a time-dependent 
manner and was significantly increased in grafts from both GFP-Tg donors transplanted into GFP-Tg recipients 
and MyD88−/− donors transplanted into GFP-Tg recipients at day 14 compared to grafts from GFP-Tg donors 
transplanted into MyD88−/− recipients at day 14 (Fig. 4A, 133.0 ± 24.0 and 153.0 ± 23.1 vs. 0.15 ± 0.10, respec-
tively, p < 0.05 (*), n = 3 in each column). In contrast, increase of TIMP-1 mRNA expression is similar between 
grafts of both genotypes over time (Fig. 4B, n = 3 each column).
As MMP-9 is produced by neutrophils in large quantities we determined if Mmp9 mRNA expression coin-
cided with the accumulation of Ly-6G positive neutrophils and performed the relevant immunohistochemistry. 
As expected, Ly-6G staining was more pronounced in grafts from MyD88−/− donors transplanted into GFP-Tg 
recipients at day 7 and 14 compared to grafts from GFP-Tg donors transplanted into MyD88−/− recipients at day 
7 (Fig. 4C) and 14 (Supplementary Figure 3). A significantly increased number of Ly-6G positive neutrophils was 
determined in grafts from MyD88−/− donors transplanted into GFP-Tg recipients at day 7 and 14 compared to 
freshly isolated small bowel (Fig. 4C, 25.4 ± 3.1 and 24.6 ± 10.8 vs. 0.3 ± 0.7, respectively, *p < 0.05, n = as indi-
cated). Further a significantly reduced number of neutrophils in grafts from GFP-Tg donors transplanted into 
MyD88−/− recipients at day 7 and 14 compared to grafts from MyD88−/− donors transplanted into GFP-Tg recip-
ients confirmed the hypothesis that large quantities of MMP-9 were produced by neutrophils (Fig. 4C, 16.3 ± 4.5 
vs. 25.4 ± 3.1 and 9.1 ± 5.7 vs. 24.6 ± 10.8, respectively, *p < 0.05, n = as indicated). Accumulation of neutrophils 
was therefore significantly increased in heterotopic intestinal grafts transplanted into mice capable of MyD88 
signalling compared to recipients deficient in MyD88 signalling. Therefore, MyD88 deficiency reduces intestinal 
inflammation, at least with respect to Mmp9 expression and neutrophil infiltration whereas development of fibro-
sis is similar in grafts of both MyD88 deficient and wildtype mice.
Discussion
In this study we investigated the role of MyD88 in the development and progression of fibrosis in an animal 
model of intestinal fibrosis. All hallmarks of intestinal fibrosis were similar in wildtype and MyD88−/− animals. 
Specifically, we found increased collagen expression, which intensified over time, virtually identical in both 
MyD88−/− and GFP-Tg grafts. Increased collagen deposition in the intestinal wall over time was detected by 
histological analysis and confirmed the real time PCR data. EvG and Sirius red staining demonstrated an identical 
network of progressively shorter-chain collagen fibrils accumulating in an IBD-mimicking fashion in grafts from 
both genotypes. We also found an increase in Tgfβ1 expression over time in both grafts. Histological staining 
Figure 3. Induction of TGF-β1 during fibrosis is independent from Myd88. (A) Real time PCR confirmed 
significant increase of Tgfβ1 expression over time (p < 0.05 (*), error bars = SEM, n = as indicated). Error 
bars = SEM. (B) IHC. In grafts a pronounced TGF-β1 staining (DAB, brown) over time was detected. 
Representative figures from n = 3.
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confirmed the increase in TGF-β1 in the obliterated lumen and the surrounding tissue. In addition, real-time 
PCR revealed a time-dependent increase of Timp1 mRNA in both grafts.
In contrast, pronounced differences between wildtype and MyD88−/− animals could also be observed. While 
Mmp9 expression was increased upon development of fibrosis we did observe a significant difference between 
the grafts from both genotypes. MyD88-signalling is a potent inducer of MMP-9 expression27,28. Likewise, 
GFP-Tg grafts transplanted into MyD88−/− recipients yielded significantly lower expression levels than the 
MyD88−/− grafts in GFP-Tg recipients. MMP-9 is produced plentifully by neutrophils29, suggesting that the 
recipient cells infiltrating the transplant are mainly responsible for the production of this mediator. Histological 
staining confirms a significantly increased number of Ly-6G positive neutrophils in the obliterated lumen in 
grafts from MyD88−/− donors transplanted into GFP-Tg recipients as compared to grafts from GFP-Tg donors 
transplanted into MyD88−/− recipients. MMP-9 is considered as a critical component of intestinal inflammation 
in IBD, but less is known concerning the role of MMP-9 in penetrating or stricturing CD. Recently, we have 
generated an anti-MMP-9 antibody, CALY-001, and have evaluated its efficacy in fibrogenesis. We showed that 
inhibiting MMP-9 significantly reduces collagen deposition and intestinal tissue remodelling30. This anti-fibrotic 
effect, associated with the anti-inflammatory effect of MMP-9 inhibitor described in the DSS-colitis model by 
Marshall and colleagues using an alternative anti-MMP-9 antibody, AB-004631, supports the development of an 
anti-MMP-9 antibody in patients with penetrating CD.
Several animal models for the study of intestinal fibrosis have been proposed32. All of them have some advan-
tages as well as disadvantages and none of them really resembles intestinal fibrosis of CD patients. Intramural 
injection of peptide glycan–polysaccharide complex at laparotomy has been shown to cause intestinal fibrosis in 
rats with immunopathological features resembling CD33. In this model, bacterial cell wall polymers were shown 
to stimulate collagen and TGF-b1 expression in intestinal myofibroblasts34. In the trinitrobenzene sulfonic acid–
induced model of colitis, rats develop colonic fibrosis and stricture formation, but this has not yet been well 
characterized35. Our animal model of intestinal fibrosis may have its own limitations.The observed increase in 
neutrophils in the heterotopic transplantation model may be affected by immune response to intestinal grafts, 
rejection, ischemia or hypoxia which contributes to fibrosis in the animal model but not necessarily to fibrosis in 
IBD patients.
Figure 4. MyD88 deficiency reduces intestinal inflammation but not the development of intestinal fibrosis. 
(A) Significant increase of Mmp9 mRNA expression in grafts isolated from GFP-Tg recipients at day 14 in 
comparison to freshly isolated intestine. Mmp9 mRNA expression in grafts from MyD88−/− recipients remained 
unchanged over time (p < 0.05 (*), error bars = SEM, n = 3 each column). (B) Timp1 mRNA expression 
remained identical over time in both grafts from GFP-Tg and MyD88−/− recipients (n = 3 each column).  
(C) IHC revealed an increase in Ly-6G+ neutrophils in grafts extracted from both GFP-Tg and MyD88−/− 
donor animals compared to freshly isolated small intestine. The number of Ly-6G positive cells (yellow crosses) 
was significantly increased in grafts extracted from GFP-Tg (p < 0.05 (*), Kruskal-Wallis One Way Analysis 
of Variance on Ranks, All Pairwise Multiple Comparison Procedures, Dunn’s Method). The number of Ly-6G 
positive neutrophils was calculated from at least four places in representative areas at 20-fold magnification. 
Mean value und standard deviation is shown. n = 4 – 7 as indicated.
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Differences in the microbiome are likely to influence development of intestinal fibrosis. The intestinal microbi-
ota that lead to a response by the innate immune system in IBD cause inflammation and may trigger fibrogenesis. 
However, there are conflicting reports on the importance of the MyD88-dependent signalling in the development 
of intestinal fibrosis. S. typhimurium ranges among the most prevalent agents of foodborne diseases and provokes 
severe inflammatory responses and thus may initiate fibrosis. Infection studies with streptomycin pretreated mice 
showed evidence for MyD88-dependent and MyD88-independent pathways in S. typhimurium colitis36. S. typh-
imurium was shown to efficiently colonize the cecal lumen and to cause the same level of inflammation in both 
MyD88+/+ and MyD88−/−36,37. S. typhimurium can efficiently induce inflammation even in the absence of MyD88 
signalling. Intestinal dendritic cells are believed to sample and present not only S. typhimurium but all commen-
sal bacteria to the gut-associated immune system. MyD88 signaling in mucosal dendritic cells is not required 
for induction of colitis by S. typhimurium38. In contrast, using a less virulent S. typhimurium strain in infection 
studies MyD88−/− mice displayed a decrease in collagen and mucosal inflammation in ceca compared to wildtype 
mice37. Submucosal inflammation and fibroblast accumulation was similar in the infected MyD88−/− and wild-
type mice37 and the authors conclude that fibrosis is not simply a secondary effect of local inflammation and tissue 
damage. Studies where S. typhimurium infection in mice was eradicated with antibiotics showed evidence that 
fibrogenesis is preceded by inflammation but eradication of the inflammatory stimulus represses inflammation 
without preventing fibrosis20. This suggests that intestinal fibrosis does not require persistent microbal stimula-
tion and could be independent from the MyD88 pathways from a certain time point onwards.
There are also conflicting reports on the importance of the MyD88-dependent signalling in the development 
of fibrosis in other organs. Kidney fibrosis studies using various murine models have shown MyD88 to be a key 
component of this disease, whereby its absence coincided with reduced inflammation and attenuated collagen 
deposition39,40. MyD88-activation was linked with a shift in the immune response towards T helper type 2 differ-
entiation and M2 polarisation of macrophages39. This pattern has previously been implicated in the development 
and progression of fibrosis41,42. Confirmatively, MyD88 signalling was found to be essential for the inflammation 
and fibrosis in a bleomycin-induced model of pulmonary disease43. The TLR4-triggered MyD88 pathway was 
found to be crucial to hepatic fibrosis by potentiating pro-fibrotic TGF-β1 signalling44. In contrast, in other stud-
ies using different models of fibrosis MyD88 signalling is less relevant for the development and progression of 
fibrosis. For instance, Leptospira interrogans induces fibrosis in mouse kidney in a MyD88-independent fashion45. 
Similarly, a recent study showed that MyD88, while relevant for the inflammatory process, plays only a minor role 
in a silica model of lung fibrosis46. Critically, MyD88-deficient mice presented a pronounced accumulation of 
pro-fibrotic cytokines and did not manifest a tempering of collagen deposition.
TLRs and NOD-like receptors are responsible for sensing local microbiota2. TLR are not only expressed in 
macrophages, dendritic cells and intestinal epithelial cells but also in primary colonic myofibroblasts47, one of the 
main producers of extracellular matrix components that are deposited during fibrosis. In mice, MyD88 is essential 
for the inflammatory responses mediated by almost all TLR family members48 as MyD88−/− show no responses to 
the TLR2 ligands peptidoglycan and lipoprotein49,50, to the TLR4 ligand lipopolysaccharide (LPS)51, to the TLR5 
ligand flagellin52, to the TLR7 ligand imidazoquinoline53 and to the TLR9 ligand CpG DNA54,55. On one hand 
MyD88 signalling is required to limit the bacterial burden and mice with a Myd88-deficiency have increased 
susceptibility to bacterial and viral infections. On the other hand MyD88-independent TLR signaling pathways 
have also been identified56–58.
Furthermore wound healing is impaired in MyD88-deficient mice. Adequate wound healing is the result of an 
exquisite physiological balance between multiple pro- and anti-fibrotic stimuli on extracellular matrix-producing 
cells59–62. Excessive tissue repair promotes fibrosis and impairs gastrointestinal function and is a common clinical 
problem in patients with IBD.
The data presented here suggest that although inflammation is reduced by MyD88 deficiency, the develop-
ment of intestinal fibrosis is uncoupled from MyD88 signalling. MyD88 is not the only adaptor protein involved 
in Toll/IL-1 receptor family signalling. Stimulation of TLR3 and TLR4 in the absence of MyD88 still leads to 
the activation of NF-kB, albeit with delayed kinetics51. Interestingly, TLR4 polymorphisms have been associated 
with an increased susceptibility for IBD63,64. The MyD88-independent TLR4 response occurs via the adaptor 
TIR domain-containing adaptor inducing IFN-beta (TRIF) which then triggers the interferon regulatory factor 
3 (IRF3)57,65 or NF-kB via RIP66. Furthermore, TLRs are not the only pattern recognition receptors involved in 
the innate immune response. Intracellular NOD/CARD-like receptors are also able to bind PAMPs67 and have 
been shown, in the case of NOD2/CARD15, to be strictly linked to CD68. However, even considering the presence 
of these alternative pathways, the acute inflammatory response will be strongly reduced without a functional 
MyD88, as exemplified by a strongly reduced accumulation of neutrophils in our experiments. Development of 
fibrosis thus appears to be uncoupled from inflammation, contradicting published concepts and theories. This 
suggests that anti-inflammatory agents – although essential to treat inflammatory flares – are not a sufficient 
treatment option against IBD associated fibrosis.
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